Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.05 -1.9%	$2.84	$1.05 ▼ $3.98	$308.44M	1.89	600,136 shs	503,903 shs
CMPX Compass Therapeutics	$3.00 -4.8%	$2.43	$0.87 ▼ $4.08	$435.59M	1.48	988,944 shs	662,402 shs
SLDB Solid Biosciences	$6.39 +10.4%	$4.26	$2.41 ▼ $10.37	$448.81M	2.34	1.23 million shs	3.44 million shs
VXRT Vaxart	$0.44 +8.7%	$0.46	$0.26 ▼ $1.07	$100.72M	1.14	2.64 million shs	1.69 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+1.63%	-5.46%	-4.59%	+156.38%	-17.37%
CMPX Compass Therapeutics	+0.64%	+10.53%	+43.84%	+80.00%	+205.83%
SLDB Solid Biosciences	+3.76%	+6.83%	+25.60%	+127.06%	-35.02%
VXRT Vaxart	+3.55%	+16.69%	-32.03%	+17.74%	-42.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.5559 of 5 stars	3.5	1.0	1.3	0.8	0.6
CMPX Compass Therapeutics	2.9321 of 5 stars	3.6	1.0	2.9	5.0	0.0
SLDB Solid Biosciences	3.3171 of 5 stars	4.6	1.0	3.3	1.7	0.6
VXRT Vaxart	3.0598 of 5 stars	3.5	5.0	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	154.10% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.67	322.22% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	136.31% Upside
VXRT Vaxart	3.00	Buy	$3.00	581.82% Upside

Current Analyst Ratings Breakdown

Latest VXRT, SLDB, CMPX, and ADCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.27	N/A	N/A	($2.10) per share	-1.45
CMPX Compass Therapeutics	$850K	488.05	N/A	N/A	$0.91 per share	3.30
SLDB Solid Biosciences	$8.09M	61.22	N/A	N/A	$3.43 per share	1.86
VXRT Vaxart	$47.40M	2.13	N/A	N/A	$0.26 per share	1.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
CMPX Compass Therapeutics	-$49.38M	-$0.41	N/A	N/A	N/A	N/A	-42.47%	-38.31%	8/11/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)
VXRT Vaxart	-$66.95M	-$0.27	N/A	N/A	N/A	-122.63%	-91.89%	-38.40%	8/14/2025 (Estimated)

Latest VXRT, SLDB, CMPX, and ADCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VXRT Vaxart	-$0.08	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/13/2025	Q1 2025	VXRT Vaxart	-$0.07	-$0.07	N/A	-$0.07	$2.85 million	$20.88 million
5/8/2025	Q1 2025	CMPX Compass Therapeutics	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
CMPX Compass Therapeutics	N/A	8.33	8.33
SLDB Solid Biosciences	N/A	10.89	10.89
VXRT Vaxart	N/A	0.64	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CMPX Compass Therapeutics	68.43%
SLDB Solid Biosciences	81.46%
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
CMPX Compass Therapeutics	29.80%
SLDB Solid Biosciences	1.90%
VXRT Vaxart	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
SLDB Solid Biosciences	100	77.51 million	76.04 million	Optionable
VXRT Vaxart	120	228.91 million	222.37 million	Optionable

VXRT, SLDB, CMPX, and ADCT Headlines

Recent News About These Companies

Vaxart (NASDAQ:VXRT) & Xenetic Biosciences (NASDAQ:XBIO) Head-To-Head Contrast

July 12, 2025 | americanbankingnews.com

Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Here's What Happened

July 11, 2025 | marketbeat.com

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

July 8, 2025 | financialpost.comF

Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why

July 3, 2025 | marketbeat.com

Vaxart (NASDAQ:VXRT) Share Price Crosses Below 200-Day Moving Average - Here's What Happened

June 25, 2025 | marketbeat.com

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 | globenewswire.com

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 | globenewswire.com

Vaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025

June 10, 2025 | quiverquant.comQ

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

June 10, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

June 2, 2025 | globenewswire.com

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025 | globenewswire.com

Vaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025

May 29, 2025 | quiverquant.comQ

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025 | globenewswire.com

Vaxart Discusses Reverse Stock Split and Capital Raise

May 28, 2025 | tipranks.com

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025 | globenewswire.com

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman

May 20, 2025 | quiverquant.comQ

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock News

May 20, 2025 | gurufocus.com

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025 | globenewswire.com

Vaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 Shares

May 20, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, SLDB, CMPX, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.05 -0.06 (-1.93%)

Closing price 03:59 PM Eastern

Extended Trading

$3.12 +0.07 (+2.30%)

As of 08:00 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Compass Therapeutics NASDAQ:CMPX

$3.00 -0.15 (-4.76%)

Closing price 04:00 PM Eastern

Extended Trading

$3.01 +0.01 (+0.20%)

As of 07:04 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Solid Biosciences NASDAQ:SLDB

$6.39 +0.60 (+10.36%)

Closing price 04:00 PM Eastern

Extended Trading

$6.46 +0.07 (+1.16%)

As of 07:55 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Vaxart NASDAQ:VXRT

$0.44 +0.04 (+8.67%)

As of 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time